HAART, DOTS and renal disease of patients co-infected with HIV/AIDS and TB in the South West Region of Cameroon by unknown
RESEARCH ARTICLE Open Access
HAART, DOTS and renal disease of patients
co-infected with HIV/AIDS and TB in the
South West Region of Cameroon
Dickson Shey Nsagha1*, Benjamin Thumamo Pokam2, Jules Clement Nguedia Assob2, Anna Longdoh Njunda2,
Odette Dzemo Kibu2, Elvis Asangbeng Tanue2, Charlotte Wenze Ayima2 and Patrick Elroy Weledji3
Abstract
Background: Tuberculosis is the commonest infection among HIV/AIDS patients. This co-infection constitutes a
major death threat in the world. There is paucity of data about renal disease amongst patients on HAART and
DOTS therapy in Cameroon.
Methods: This was a hospital-based cross-sectional study in the Buea, Limbe and Kumba government Hospitals.
Spectrophotometric method was used for the quantitative determination of serum creatinine, urea, albumin and
total protein levels. Glomerular filtration rate was estimated using the MDRD method. The student’s t test, ANOVA
and logistic regression were used to analyse the data.
Results: Out of 200 participants, 101 (50.5 %) were males. The ages ranged from 21 to 65 years with a mean age of
38.04 ± 10.52 years. Compared to adults on DOTS alone, adults on HAART alone had a significantly higher prevalence
of eGFR <60 ml/min/1.73 m2 (10/70 (14.3 %) vs. 1/70 (1.4 %), OR = 11.5 [1.4–92.5], p = 0.02) while more participants on
HAART/DOTS had significantly higher serum creatinine (18/60 (30 %) vs 10/70 (14.3) OR = 2.57 [1.08–6.12], p = 0.033).
Though participants on HAART/DOTS combined therapy had low eGFR, the association was not statistically significant
(OR = 6.27, 95 % CI;0.71–55.27, p = 0.098). Participants on the Zidovudine, Lamivudine, Nevirapine regimen showed a
statistically significant difference in the mean serum creatinine and albumin levels between the HAART/DOTS
combined therapy and HAART group (p = 0.0219 and 0.0001 respectively).
Conclusion: Compared to adults on DOTS, adults on HAART were more likely to have renal dysfunction
(eGFR <60 ml/min per 1.73 m2). Adult on a combination of HAART and DOTS had a similar prevalence of
renal dysfunction as those on HAART alone. This study showed that the use of the HAART regimen
(Tenofovir, Lamivudine and Efavirenz combination) among the HAART treated adults was nephrotoxic.
However, other combined HAART and DOTS regimens had no nephrotoxic effect. Abnormal kidney function
can be associated with HAART use.
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Background
Worldwide, tuberculosis (TB) is the commonest oppor-
tunistic infection affecting 40 % of people living with
HIV/AIDS (PLWHA) and it remains the commonest
cause of death in patients with AIDS. Highly Active
Antiretroviral Therapy (HAART) is a combination of
antiretroviral drugs for the management of HIV/AIDS
[1]. Directly Observed Therapy, Short-course (DOTS), is
the recommended therapy for TB treatment by the
World Health Organization (WHO). This is a combin-
ation of isoniazid, rifampin, pyrazinamide and etham-
butol for 8 weeks, followed by isoniazid and rifampin for
a further 4–7 months (standard therapy) [2].
The association between HIV and renal disease was re-
ported in 1984 by investigators in New York and Miami,
on a series of HIV-1 seropositive patients who developed
a renal syndrome characterized by progressive renal fail-
ure and proteinuria [3]. HIV-1 infects renal cells and the
kidney may be an important long term reservoir for the
virus. Problems with kidney function in HIV infected
people may be due to medications or the HIV itself.
These can range from minor changes in fluid and elec-
trolyte balance to end-stage renal disease requiring dialy-
sis [4]. Patients on anti-tuberculosis treatment may
develop acute kidney injury (AKI), but little is known
about the renal outcome and prognostic factors. A study
by Chai-Hao and colleagues [5] showed that 99 out of
1394 (7.1 %) patients on anti-TB treatment had AKI.
Sixty (4.3 %) developed AKI within two months of anti-
TB treatment, including 11 (0.7 %) with a prior history
of rifampin exposure. Thirty (2.2 %) had co-morbid
chronic kidney disease or end-stage renal disease.
Worldwide, patients with TB and HIV co-infection are
estimated to be over one million [6]. The burden of this
co-infection is particularly high in sub-Saharan Africa
[6]. In Cameroon the prevalence of TB among HIV-
infected adults was 38 % in 2013 [7]. Tuberculosis and
HIV/AIDS have been closely linked since the emergence
of AIDS [8].
Treatment of patients co-infected with HIV and tuber-
culosis increase the rate of mortality due to drug inter-
action, overlapping toxicity and side effects [9, 10].
Assessing the effect of this combined treatment on kid-
ney function is not routinely done in hospitals in
Cameroon. Hence, patients receiving this combined
treatment may slowly develop kidney failure if they are
not properly managed and monitored for any nephrotoxic
effect of the combined therapy. These patients may end
up having kidney failure or worse still lose their kidney in
the long run. A kidney transplant will not be an easy op-
tion since it is very expensive and it is not done in
Cameroon. Patients may take the option of hemodialysis
which is also time consuming and expensive. Kidney func-
tion seems to be altered in patients receiving HIV and TB
treatment. The study therefore, investigated the associ-
ation between HAART, DOTS and kidney function of
these patients in order to determine any nephrotoxic ef-
fects associated with such management.
Methods
Study design and setting
This was a hospital-based cross-sectional study carried
out between April and July 2014 at the Buea, Limbe and
Kumba government Hospitals. These are state-owned
hospitals in the South-Western Region of Cameroon.
These hospitals accommodate patients from other areas
of the South-Western Region, providing health services
to more than 40,000 inhabitants from this part of the
country. A time limited sampling technique was used,
where patients were consecutively recruited throughout
the study period.
Participants
Participants involved patients who visited the HIV/AIDS
and TB treatment centers of the Buea, Limbe and
Kumba government Hospitals. Concerned participants
were those on HAART, DOTS or on the combined ther-
apy (HAART/DOTS). Two hundred participants were
enrolled into the study and they all satisfied the inclu-
sion criteria.
Inclusion and exclusion criteria
Participants on HAART, DOTS and combined HAART
and DOTS were enrolled into the study. Adults who
were 21 years of age and above were included. This is
because according to the Cameroon code for the classifi-
cation of adults, adulthood begins at the age of 21 years.
Also, studies have shown HIV and TB co-infection to be
the commonest cause of death among adults in many
countries [11]. However, we excluded participants with
known renal disease or pregnancy.
Sample size determination
The prevalence of kidney disease was estimated to be
10 % using the formula for sample size calculation [12].
n ¼ zð Þ2p 1−pð Þe2 Where n = sample size, Z = constant = 1.96,
p = Estimated prevalence = 10 %, e = precision of the event




A structured questionnaire was administered to each
participant to obtain socio-demographic characteristics
and medical history. Hospital records of the participants
were also reviewed to obtain information about the type
of drug regimen and duration of treatment.
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Laboratory procedures
Blood samples were collected from each participant
through venipuncture using a vacutainer needle.
About 5 ml of venous blood was collected in plain
tubes. The blood samples were allowed to clot at
room temperature before centrifuged at 3000 rpm for
5 min to obtain the serum. These sera were stored at
a temperature of -20 °C and the measurements of
serum creatinine, urea, albumin and total protein
were analysed later in batches using a MINDRAY
spectrophotometer. This is a BA-88A semi-auto
chemistry analyzer with a touch-screen and pop-up
keypad. This analyzer supports bi-chromatic tests for
end point, fixed-time and kinetics methods.
For serum creatinine, the Jaffe kinetic method was
used [13] while urea was analysed using the kinetic
method [14]. The colorimetric method was used for the
quantitative determination of serum albumin [15] and
serum total protein [16]. The INMESCO kit was used
for serum creatinine, urea, albumin and total protein.
The estimated glomerular filtration rate (eGFR) was cal-
culated using the Modification of Diet in Renal Disease
(MDRD) equation considering the ethnic factor for the
black race [17].
The study classified kidney disease based on the
Kidney Disease Improving Global Outcomes (KDIGO)
guidelines [18]. Decreased Renal function was defined
as eGFR <60 ml/min per 1.73 m2 and no known kid-
ney disease when eGFR ≥60 ml/min per 1.73 m2 and
a stable serum creatinine. Reference ranges for renal
function tests were set as follows; serum creatinine:
0.6–1.1 mg/dl, serum urea: 10–50 mg/dl, serum albu-
min: 35–52 g/l, serum total protein: 66–86 g/l. The
participants on DOTS were set as the reference
group. In the logistic regression analysis for factors
associated with abnormal laboratory parameters, a
serum creatinine of >1.1 mg/dl, eGFR of <60 ml/min
per 1.73 m2, serum albumin of >52 g/l and serum
total protein of > 86 g/l were considered abnormal.
Data management and analysis
Data obtained from each participant was entered into a
log book and this was checked by the lead author. The
data was de-identified prior to analysis and later keyed
into a computer using Microsoft excel, 2010 (Microsoft
Corporation Inc. USA) and verified for the possibility of
entering errors. Statistical analysis was conducted using
STATA version 11. Student’s t-test was used to compare
the differences between group means. Logistic regression
analysis was used to determine the association between
the treatment groups and kidney function tests. ANOVA
was used to determine the difference in proportion
amongst the three treatment groups. Statistical signifi-
cance was set at p < 0.05 at 95 % confidence interval [12].
Ethical approval
This study was approved by the Faculty of Health Sciences
Institutional Review Board (FHSIRB) of the University of
Buea, Cameroon (reference number: 2014-02-0199). A
signed written consent form was obtained from each par-
ticipant before enrollment into the study.
Results
A total of 216 patients were contacted but only 200 were
consecutively recruited during the study period. These 16
were excluded because they provided incomplete informa-
tion with regard to medical history and demographic char-
acteristics such as age. Baseline characteristic of the study
population is described in Table 1. Out of two hundred
adults enrolled into the study, 87 (43.5 %) were from the
Buea Regional Hospital, 62 (31.0 %) from the Limbe
Regional Hospital and 51 (25.5 %) from the Kumba
District Hospital. Out of the 200 participants, 119
(59.5 %) were from the urban areas while 81 (40.5 %)
were from the rural areas. Overall, there were 101
(50.5 %) male participants and 99 (49.5 %) females.
The ages ranged from 21–65 years with the mean age
being 38.04 (±10.52) years. The 200 participants were
divided into three treatment groups. Sixty (30 %) par-
ticipants were on HAART and DOTS combined treat-
ment, 70 (35 %) were on HAART and 70 (35 %) were
on DOTS.
Out of 130 participants on HAART and HAART/
DOTS, a total of 80 (61.54 %) were of the combination
of Zidovudine, Lamivudine, and Nevirapine; 6 (4.62 %)
on Zidovudine, Lamivudine, and Efavirenz while 44
(33.85 %) on Tenofovir, Lamivudine, and Efavirenz. Re-
garding the 130 participants on DOTS and HAART/
DOTS, a total of 63 (48.5 %) were on the drug regimen
rifamycin, isoniazid, ethambutol, pyrazinamide (intensive
phase) and 67 (51.5 %) were on rifamycin, isoniazid
(continuation phase).
Table 2 shows the prevalence of decreased renal dis-
ease in the three treatment groups. Participants on
HAART only, had the highest prevalence 10 (14.3 %) of
decreased renal function, followed by the HAART/
DOTS combined group 5 (8.3 %) and the DOTS group
had the lowest 1 (1.4 %). However, the overall prevalence
in the three treatment groups was 16 (8.0 %). Partici-
pants on HAART treatment for more than 2 years had a
lower prevalence of decreased renal function 4/33 (12 %)
compared to those on HAART treatment for ≤ 2 years 6/
37 (16 %) (p = 0.6260).
Logistic regression showed that significantly more par-
ticipants on HAART had low eGFR than those on
DOTS alone (p = 0.022). Also, significantly more partici-
pants on HAART/DOTS recorded high serum creatinine
than those on DOTS, with a 95 % CI odds ratio of 2.57
(1.08–6.12) (p = 0.033). Serum albumin of 53 g/l and
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higher was significantly associated with HAART treat-
ment (OR = 11.77, 95 % CI: 2.6–53.0, p = 0.001). Being
on HAART/DOTS therapy was significantly associated
with high levels of serum total protein (p = 0.023), with a
95 % CI odds ratio of 2.41 (1.13–5.14) (Table 3).
Table 4 shows the bi-variable analysis used to esti-
mates the impact of HIV, HAART and DOTS status to
renal function parameters. Participants on HAART had
a significantly higher risk of low eGFR than those on
DOTS alone even after adjusting for the differences in
HAART, HAART/DOTS therapy and age (aOR = 3.5
[1.1-11.3]). Further adjustment for gender and BMI did
not change these estimates. Also, more participants had
significantly higher risk of high serum creatinine and high
serum total protein even after adjusting the differences in
HAART, HAART/DOTS, age, BMI and hypertension
(aOR = 11.9 [3.32–42.54] and OR = 6.0 [1.77–19.98]
respectively).
The mean eGFR was significantly higher in patients
on HAART than those on HAART/DOTS with respect
to Zidovudine, Lamivudine, Nevirapine combination
[126.0 (±83.44) and 95.38 (±26.51), p = 0.039]. Also, the
mean serum albumin was significantly higher in pa-
tients on HAART alone than those on HAART/DOTS
with respect to Zidovudine, Lamivudine, Nevirapine
combination [49.26 (±5.76) and 38.07 (±8.95), p =
0.001]. No significant difference was found in mean
serum creatinine between patients on HAART and
those on HAART/DOTS with respect to Tenofovir,
Lamivudine, Efavirenz combination. However, patients
on HAART had abnormal higher value of mean serum
creatinine compared to those on HAART/DOTS [2.06
(±4.16) and 0.97 (±0.28), p = 0.217].
No significant difference was found in mean serum
creatinine between patients on DOTS and those on
HAART/DOTS at the intensive phase of TB treatment
[0.97 (±0.24) and 0.95 (±0.22), p = 0.752]. Also, no sig-
nificant difference was observed in mean serum creatin-
ine between patients on DOTS alone and those on
HAART/DOTS at the continuation phase of TB treat-
ment [1.04 (±0.17) and 1.09 (±0.33), p = 0.443]. The
mean serum total protein was significantly higher in pa-
tients on HAART/DOTS than those on DOTS at the
continuation phase of TB treatment [86.84 (±15.66) and
78.84 (±8.65) p = 0.016].
Discussion
Tuberculosis is the commonest associated opportunistic in-
fection among HIV infected individuals. This increases the
mortality rate in PLWHA. However, HAART and DOTS
are currently being used to fight these infections [19].
In our study, HIV-infected adults being treated with
HAART alone, were about 12 times more likely to de-
velop low levels of eGFR compared to HIV negative TB-
Table 1 Baseline characteristics of the study population
Frequency no (%)



















eGFR (ml/min/1.73 m2) <60 16 (8.0)
≥60 184 (92.0)
Total 200 (100)
Treatment groups HAART 70 (35.0)
DOTS 70 (35.0)
HAART/ DOTS 60 (30.0)
Total 200 (100)
Type of HAART AZT/3TC/NVP 46 (65.7)
1 HAART group (n = 70) AZT/3TC/EVP 3 (4.3)
TNV/3TC/NVP 21 (30.0)





1 DOTS group (n = 70)
RIF/INH/ETH/PZA 38 (54.3)
RIF/INH 32 (45.7)
2 HAART/DOTS group (n = 60) RIF/INH/ETH/PZA 25 (41.7)
RIF/INH 35 (58.3)
Total 130 (65)
Key: AZT/3TC/NVP Zidovudine, Lamivudine, Nevirapine, AZT/3TC/EFV
Zidovudine, Lamivudine, Efavirenz, TDF/3TC/EFV Tenofovir, Lamivudine,
Efavirenz, HAART Highly Active Antiretroviral Therapy, DOTS Direct Observed
Therapy, Short-course, RIF/INH/ETH/PZA rifamycin, isoniazid, ethambutol,
pyrazinamide, RIF/INH rifamycin, isoniazid
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infected adults on DOTS therapy. Our findings are similar
to the study carried out by Owiredu and colleagues [20].
They proved that 11 % of the participants on HAART had
low eGFR values. However, Msango and colleagues [21]
found a higher prevalence of renal dysfunction among
HIV patients starting antiretroviral therapy in Tanzania.
Gallant and colleagues [22] demonstrated that participants
on HAART had a significant decline in eGFR especially
those on tenofovir and protease inhibitors. This finding
from our study might be due to the nephrotoxic effect of
HAART and the duration of HAART use. Serum creatin-
ine was also statistically significantly higher in the HAART
group compared to the DOTS group. Mainasara and col-
leagues [23] showed that, the level of serum creatinine
was significantly high among participants on HAART
than those not on HAART. The result of this study was
contrary to the findings of Kamga and colleagues [24] who
reported that the mean serum creatinine was significantly
higher in the antiretroviral treatment (ART) naïve group
when compared to those who were already on ART.
Critically studying the different HAART regimens, the
mean serum creatinine and eGFR of Zidovudine,
Lamivudine, Nevirapine combination were within the
normal range with a statistical significant difference be-
tween the HAART group and combined HAART/DOTS
group. Our findings were contrary to a study carried out
by Lidia and colleagues who observed a variety of
HAART-related renal side effects associated differently
to ARV classes or single drugs [25]. Another study
showed that, a more serious but less common side effect
of Zidovudine, Lamivudine, Nevirapine is the damage to
the liver, severe rash and a condition called lactic acid-
osis, which may cause pancreatitis, or renal failure. How-
ever, HAART interacts with rifampicin [26]. Rifampicin
(member of rifamycin class), a key component of
short-course chemotherapy for TB, is a potent in-
ducer of the cytochrome P450 enzyme system that
metabolizes several drugs including non-nucleoside
reverse transcriptase inhibitor (NNRTI) antiretroviral
agents [27]. Cytochrome p450 increases the metabol-
ism of NNRTI and their metabolites are excreted in
urine. Thus, due to drug- drug interaction between
DOTS and HAART, the therapeutic levels of these
NNRTIs are greatly reduced in plasma.
Table 2 Prevalence of decreased renal function by the KDIGO definition
Parameter HAART group n (%) DOTS group n (%) HAART/DOTS group n (%) Total n(%) p = value
eGFR
<60 ml/min/1.73 m2 10 (14.3) 1 (1.4) 5 (8.3) 16 (8.0) 0.02
≥60 ml/min/1.73 m2 60 (85.7) 69 (98.6) 55 (91.7) 184 (92.0)
Key: eGFR estimated Glomerular Filtration Rate, DOTS Direct Observed Therapy Short-course, HAART Highly Active Antiretroviral Therapy
Table 3 Logistic regression of serum creatinine, eGFR, albumin, and total protein
Parameter Number examined No (%) COR 95 % CI p- value
Creatinine
DOTS only* 70 10(14.3 %) 1 - -
HAART only 70 17(24.3 %) 1.92 0.81–4.56 0.138
HAART/DOTS 60 18(30.0 %) 2.57 1.08–6.12 0.033
eGFR
DOTS only* 70 1(1.4) 1 - -
HAART only 70 10(14.3) 11.50 1.43–92.47 0.022
HAART/DOTS 60 5(8.3) 6.27 0.71–55.27 0.098
Albumin
DOTS only* 70 2(2.9) 1 - -
HAART only 70 18(25.7) 11.77 2.6–53.0 0.001
HAAT/DOTS 60 1(1.7) 0.58 0.05–6.52 0.656
Protein
DOTS only* 70 16(22.9) 1 - -
HAART only 70 25(35.7) 1.88 0.89–3.94 0.097
HAART/DOTS 60 25(41.7) 2.41 1.13–5.14 0.023
Key: *Reference group, COR Crude Odd Ratio, eGFR estimated Glomerular Filtration Rate, DOTS Direct Observed Therapy, Short-course, HAART Highly Active
Antiretroviral Therapy. Logistic regression
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For the participants on HAART (Tenofovir, Lamivu-
dine, Efavirenz), the mean serum creatinine was higher
above normal compared to the HAART/DOTS partici-
pants. This is line with a study that have shown that,
among nucleoside reverse transcriptase inhibitors, Teno-
fovir (TDF) is associated with renal adverse effects [25].
TDF toxicity mainly involves the renal tubule, account-
ing for clinical manifestations varying from Fanconi’s
syndrome to acute tubular necrosis. Recent reports have
also linked TDF-based HAART regimens to glomerular
injury, characterized by mild and time-dependent eleva-
tions in serum creatinine [25]. In a study carried out by
Labarga [28] entitled “Kidney tubular abnormalities in
the absence of impaired glomerular function in HIV pa-
tients treated with Tenofovir”, HIV patients on TDF had
higher prevalence of tubular damage compared to those
on other ART as well as among the ART-naïve individ-
uals. Tenofovir has been shown to cause renal tubular
cell toxicity by impairing mitochondrial function, inter-
fering with tubular transport, increasing oxidative stress,
or forming free radicals. Our results may be contrary to
Labarga’s findings because of the small number of pa-
tients on Tenofovir.
There was no statistically significant difference in
mean creatinine between the DOTS and HAART/DOTS
group at the intensive and the continuation phase. This
result tallies with the work of Dinesh and colleagues
[29], in which they were able to determine that, serum
level of creatinine was normal before and after anti-
tuberculosis treatment. This may be because Strepto-
mycin was not used in the patients enrolled in our study.
One of the side effects of Streptomycin is nephrotoxicity.
This may explain why the level of serum creatinine in
patients on combined HAART/DOTS group and DOTS
group was normal. Contrary to previous studies, the in-
cidence of rifampicin nephrotoxicity varies from 1.8–
16 % of all acute renal failure. Glomerulonephritis
presenting as proteinuria with acute onset deterioration
of renal functions may occur [26]. The duration of ther-
apy seems important and cases have been reported after
two months of therapy; although reactions as early as
13 days have also been seen [26]. The possibility of
nephrotoxic interaction between isoniazid and pyrazina-
mide also exists [26]. Chia-Hao and colleagues [5] also
reported a 7.1 % prevalence of AKI in patients on anti-
TB treatment. Within two months of intensive anti-TB
treatment, 4.3 % developed AKI with 0.8 % of them
reporting a prior history of rifampin exposure [5]. Our
results were contrary to those of Chia-Hao and col-
leagues [5] because they worked on an aging population
while we concentrated on an adult population with a
mean age of 38.04 (±10.52) years.
The primary outcome of the present study was renal
dysfunction. HIV treatment drugs are associated with
decline eGFR below 60 ml/min/1.73 m2 and elevated
serum creatinine values. Nephrotoxicity resulting from
these abnormal biochemical parameters were the sec-
ondary outcomes. These drugs fight the progression of
HIV and TB but pose a challenge to the kidney function
of those receiving them. However, our results show very
high prevalence of kidney disease in the 3 treatment
groups. This is contrary to what we had estimated in our
power calculation.
This study has limitations, particularly related to the
cross-sectional design and the small sample size in the
three treatment groups. Also, patients on treatment for
HIV and tuberculosis had been on treatment for different
lengths of time. In addition, measures of renal function
were not repeated after three months to determine if kid-
ney disease was acute or chronic. Also, urine microalbu-
min was not performed and spectrophotometric analysis
could be influenced by temperature, pH, impurities and
contaminants with a resultant change in the absorption
properties of the sample leading to inaccurate readings.
Table 4 Association of HAART and other variables with renal function paramaters
eGFR P-value Serum
creatinine
P-value Serum albumin P-value Serum total
protein
P-value
HAART 6.9 (0.79–59.5) 0.080 2.5 (0.94–6.43) 0.064 12.8 (2.74–59.57) 0.001 2.0 (0.92–4.37) 0.079
Adjusted for HAART + HAART/DOTS 4.6 (0.49–42.2) 0.181 2.6 (0.97–6.72) 0.058 0.58 (0.5-6–71) 0.664 2.1 (0.97–4.71) 0.060
Adjusted for HAART + HAART/DOTS + Age
(>40 years)
3.5 (1.1–11.3) 0.036 1.1 (0.52–2.40) 0.775 0.36 (0.11–1.24) 0.107 1.7 (0.88–3.22) 0.113
Adjusted for HAART + HAART/DOTS + Age
(>40 years) + Gender (female)
6.0 (1.41–25.61) 0.015 0.7 (0.35–1.63) 0.488 0.95 (0.34–2.67) 0.931 1.4 (0.75–2.74) 0.270
Adjusted for HAART +HAART/DOTS + Age
(>40 years) + Gender (female) + BMI (≥25 kg/m2)
4.8 (1.48–15.35) 0.009 2.2 (1.0–4.85) 0.050 1.01 (0.31–3.27) 0.982 0.7 (0.35–1.59) 0.449
Adjusted for HAART +HAART/DOTS + Age
(>40 years) + Gender (female) + BMI
(≥25 kg/m2) + Hypertension
3.9 (0.56–26.63) 0.170 11.9 (3.32–42.54) <0.001 1.42 (0.14–14.53) 0.770 6.0 (1.77–19.98) 0.004
Key: BMI body mass index, DOTS Direct Observed Therapy, Short-course, HAART Highly Active Antiretroviral Therapy, Reference group participants on DOTS
Nsagha et al. BMC Public Health  (2015) 15:1040 Page 6 of 8
Conclusion
Compared to adults on DOTS, adults on HAART were
more likely to have renal dysfunction (eGFR <60 ml/min
per 1.73 m2). Adult on a combination of HAART and
DOTS had a similar prevalence of renal dysfunction as
those on HAART alone. This study showed that the use
of the HAART regimen (Tenofovir, Lamivudine and Efa-
virenz combination) among the HAART treated adults
was nephrotoxic. However, other combined HAART and
DOTS regimens had no nephrotoxic effect. Abnormal
kidney function can be associated with HAART use. The
DOTS were less nephrotoxic and some of the drugs
such as rifamycin reduced the nephrotoxicity of
HAART. It is possible to suggest that less toxic regimens
should be used in the management of HIV/AIDS and
TB co-infected patients.
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